Chronic Obstructive Pulmonary Disease :COPD.
Conditions
Interventions
Conventional Treatment Group:Patients will receive standard therapy for acute exacerbation of COPD according to the 2024 GOLD guideline.
Conventional Treatment plus Fecal Microbiota Transplantation Group:Patients will receive standard therapy for acute exacerbation of COPD according to the 2024 GOLD guideline, in combination with fecal
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 80 years, regardless of sex. 2. Meeting the diagnostic criteria for acute exacerbation of COPD according to GOLD 2024. 3. Patients with an mMRC score >= 2 or a CAT score >= 10, and eligible for nasojejunal or colonic catheterization. 4. Patients or their legal representatives are able to understand the study protocol, willing to participate, and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Known allergy to any component of the investigational product used in this study. 2. Presence of major diseases or conditions other than COPD which, in the opinion of the investigator, may expose the subject to increased risk from participation or interfere with study results or the subject’s ability to participate. 3. Gastrointestinal diseases: (1) Patients with known organic gastrointestinal diseases; (2) Patients with concurrent intestinal co-infections, such as *Clostridium difficile*, enterohemorrhagic *Escherichia coli*, *Salmonella*, *Shigella*, *Campylobacter*, *Yersinia*, or cytomegalovirus. 4. Pregnant or lactating women. 5. Patients with a history of gastrointestinal or pulmonary surgery. 6. Participation in another COPD-related clinical trial at the time of enrollment or within 3 months prior to enrollment; or the presence of severe primary diseases involving the heart, liver, kidney, hematopoietic system, or other major organs/systems. 7. Patients with congenital or acquired immunodeficiency. 8. Patients who have received cytotoxic drugs such as rituximab, cyclophosphamide, or methotrexate within the past 3 months. 9. Patients with long-term (= 4 weeks) use of medium- to high-dose corticosteroids. 10. Severe immunosuppression, e.g., neutrophil count < 0.5 × 10?/L. 11. Participation in other clinical trials that may interfere with the evaluation of this study. 12. Any other condition that, in the judgment of the investigator, makes the subject unsuitable for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Blood Count (CBC);Inflammatory markers (e.g., C-reactive Protein [CRP], Procalcitonin [PCT]);Routine Biochemical Tests;Arterial Blood Gas Analysis (ABG);Pulmonary Function Test (PFT);Pulmonary Imaging Examination;Modified Medical Research Council (mMRC) Dyspnea Scale Assessment;COPD Assessment Test (CAT) Evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Immune Function Markers;Cardiac Enzyme Profile;D-dimer;B-type Natriuretic Peptide (BNP); | — |
Countries
China
Contacts
Public ContactLi Jiabin
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed